ValuEngine upgraded shares of Agenus Inc. (NASDAQ:AGEN) from a strong sell rating to a sell rating in a report released on Monday.
A number of other analysts have also recently weighed in on the stock. HC Wainwright set a $5.00 price target on shares of Agenus and gave the stock a hold rating in a research note on Saturday, May 6th. Zacks Investment Research upgraded shares of Agenus from a sell rating to a buy rating and set a $4.50 price target for the company in a research note on Wednesday, July 5th. Finally, Maxim Group reiterated a buy rating and set a $7.00 price target on shares of Agenus in a research note on Sunday, April 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Agenus has a consensus rating of Buy and a consensus target price of $5.88.
Shares of Agenus (NASDAQ:AGEN) opened at 5.26 on Monday. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The stock’s market capitalization is $521.36 million. The stock has a 50 day moving average price of $4.14 and a 200 day moving average price of $3.89.
Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.14. The firm had revenue of $26.96 million for the quarter, compared to the consensus estimate of $5.22 million. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%. Equities research analysts anticipate that Agenus will post ($1.23) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Agenus Inc. (AGEN) Raised to “Sell” at ValuEngine” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://sportsperspectives.com/2017/07/27/agenus-inc-agen-raised-to-sell-at-valuengine.html.
A number of hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of Agenus by 3,447.2% in the first quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock worth $2,539,000 after buying an additional 654,351 shares in the last quarter. Credit Suisse AG boosted its stake in shares of Agenus by 167.9% in the first quarter. Credit Suisse AG now owns 159,806 shares of the biotechnology company’s stock worth $602,000 after buying an additional 100,149 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Agenus by 12.2% in the first quarter. Metropolitan Life Insurance Co. NY now owns 55,920 shares of the biotechnology company’s stock worth $211,000 after buying an additional 6,101 shares in the last quarter. Highbridge Capital Management LLC acquired a new stake in shares of Agenus during the first quarter worth $391,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Agenus by 6.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 267,159 shares of the biotechnology company’s stock worth $1,008,000 after buying an additional 16,074 shares in the last quarter. Hedge funds and other institutional investors own 42.61% of the company’s stock.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.